Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMUS: Pembrolizumab Maintenance in sNSCLC
NCT02564380Phase 2Terminated
- Sponsor
- AIO-Studien
- Start
- Jan 2016
- Primary completion
- May 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in squamous cell carcinoma of the lung (SCCL), sponsored by AIO-Studien. Started Jan 2016; status: terminated.
02
Drugs
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT02564380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02564380.